-+ 0.00%
-+ 0.00%
-+ 0.00%

Xinovi announced that in order to ensure the smooth progress of the new drug R&D fund-raising project, the company plans to use the raised capital to increase capital for the two wholly-owned subsidiaries, including Shanghai Xinovi Biomedical Co., Ltd. by 500 million yuan and Shandong Xinovi Pharmaceutical Technology Co., Ltd. by 10 million yuan, for a total of 510 million yuan. The capital increase funds are limited to corresponding fund-raising projects and cannot be used for other purposes. This capital increase does not involve related transactions, does not constitute a major asset restructuring, and will not change the scope of the company's consolidated statements. The capital increase has already been reviewed and approved by the board of directors of the company, and there is no need to submit it to the shareholders' meeting

Zhitongcaijing·09/23/2026 11:01:33
Listen to the news
Xinovi announced that in order to ensure the smooth progress of the new drug R&D fund-raising project, the company plans to use the raised capital to increase capital for the two wholly-owned subsidiaries, including Shanghai Xinovi Biomedical Co., Ltd. by 500 million yuan and Shandong Xinovi Pharmaceutical Technology Co., Ltd., a total of 510 million yuan. The capital increase funds are limited to corresponding fund-raising projects and cannot be used for other purposes. This capital increase does not involve related transactions, does not constitute a major asset restructuring, and will not change the scope of the company's consolidated statements. The capital increase has already been reviewed and approved by the board of directors of the company, and there is no need to submit it to the shareholders' meeting